You are here:

Forthcoming Submission: pembrolizumab (Keytruda) (cHL)

Indication: monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

Drug Details

Drug Name: pembrolizumab (Keytruda) (cHL)
Drug Manufacturer: MSD
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
4/12/2017
SMC Meeting Date: 6/02/2018
Advice Due: 12/03/2018

Back